Which Peptides Did the FDA Advisory Committee Recommend in 2026?

The FDA’s Pharmacy Compounding Advisory Committee recommended adding six peptides-BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax-to the Section 503A bulk drug substances list at its July 23–24, 2026 meeting. Emideltide (also called DSIP) was the only peptide that failed to secure a majority yes vote. The panel’s advice is non-binding, but the FDA usually follows it when it later issues a proposed rule about which substances compounding pharmacies may use.

• The committee voted 8–6 in favor of BPC-157, KPV and TB-500 and 7–5 in favor of MOTS-c on July 23, 2026. (washingtonpost.com)
• On July 24 the panel backed Epitalon 7–4 and Semax 8–5, but rejected Emideltide 6–7. (statnews.com)
• PCAC recommendations affect whether state-licensed 503A pharmacies can legally compound a bulk substance when prescribing physicians document clinical need.
• The FDA staff had advised voting “No” on all seven peptides due to limited safety and efficacy data, but the committee disagreed on six. (fda.gov)
• Nothing changes immediately: the FDA must publish a proposed rule, take public comments, and issue a final rule before compounders may use the newly recommended peptides.

PCAC is the FDA’s expert panel for 503A compounding substances

The Pharmacy Compounding Advisory Committee advises the FDA on whether specific bulk drug substances should be eligible for human compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. The 14-member panel includes physicians, pharmacists, toxicologists, and patient representatives who review FDA briefing documents and public testimony before taking non-binding votes. (fda.gov)

Why the list matters: If a peptide is not on the 503A bulks list, a state-licensed pharmacy generally cannot compound it for a patient-even with a prescription-unless the drug is in shortage. Adding a substance therefore opens the door to legal prescriptions through compounding pharmacies and some telehealth services. For more background see our guide to peptide regulations.

These six peptides won PCAC support in 2026

The committee recommended six peptides across two voting days, each considered in both free-base and acetate salt forms. All six will move forward to FDA rulemaking; Emideltide will not unless the FDA overrides the vote.

Vote counts are taken from live meeting reporting in The Washington Post (Day 1) and STAT (Day 2). (washingtonpost.com)

How the committee voted-and why margins were razor-thin

All seven substances received split decisions, reflecting deep disagreements over data quality and patient access. FDA’s career scientists reviewed each peptide and recommended a “No” vote, citing inadequate human studies, potential impurities, and the existence of approved alternatives. Committee members appointed by Health Secretary Robert F. Kennedy Jr. argued that compounding could steer patients away from the gray market. (washingtonpost.com)

What happens next in the FDA rulemaking process

PCAC votes are advisory; the agency must still go through notice-and-comment rulemaking. Historically the FDA follows the committee’s advice more than 80 percent of the time, but it is not obligated to do so. After reviewing meeting transcripts, the agency will:

Draft a proposed rule: The proposal will state whether each peptide (both free-base and acetate forms) should be added to the bulks list.
Open a 60-day public comment period: Stakeholders-including patients, clinicians, compounders, and manufacturers-can submit evidence.
Publish a final rule: Only after the final rule appears in the Federal Register can pharmacies legally start compounding the newly listed peptides.

In past cycles this timeline has ranged from 9 to 18 months. Until then, pharmacies may compound a peptide only if the commercial version is in active shortage, which is not the case for any of the seven substances.

What the recommendations mean for patients and providers

If finalized, the decision could expand legal access to some popular wellness peptides, but it won’t equal FDA approval. Compounded drugs are not evaluated for safety, efficacy, or quality in the way approved drugs are. Prescribers must still document why an FDA-approved treatment does not meet the patient’s needs.

Potential scenarios once the rule is final:

Physician-directed prescriptions: Doctors could write individualized prescriptions for compounded BPC-157 or Semax, for example, when they believe no FDA-approved option suits the patient.
Telehealth growth: Online clinics may add newly listed peptides to their formularies, increasing mail-order availability-though state laws vary.
Insurance coverage: Compounded peptides are almost always cash-pay. Patients should compare prices and verify batch potency when choosing a pharmacy.
Quality oversight: 503A pharmacies remain subject to state board inspection, but not the FDA’s current Good Manufacturing Practice (cGMP) rules that apply to commercial drugmakers.

For guidance on evaluating peptide vendors, see our checklist for safe peptide prescriptions and the ongoing FDA peptide review tracker.

Key safety concerns raised by FDA scientists

The agency’s internal reviewers cited four recurring red-flags across the dossiers:

Limited human data: Most studies are small, open-label or non-randomized, limiting certainty about benefit-risk balance.
Impurity profiles: Synthetic peptides can contain truncated sequences or residual solvents that standard peptide tests may miss.
Immunogenicity: Repeated injections of foreign amino-acid chains may trigger antibody formation or hypersensitivity reactions.
Better-studied alternatives exist: FDA-approved biologics treat ulcerative colitis, while several approved triptans are available for migraine, calling into question medical necessity.

Those concerns remain even if the peptides reach the bulks list, underscoring the need for informed consent and post-prescription monitoring.